American Association of Clinical Endocrinology

04/25/2026

Catch up on highlights from Day 3 of . Thank you to our community for an amazing Annual Meeting. See you next year in San Diego!

04/24/2026

The current single center study suggests that CS is more common than previously described and highlights that adrenal CS is the most common etiology. These data should increase recognition and screening for this potentially life-threatening disorder. Read more: https://www.endocrinologydiabetes.org/article/S3050-9157(25)00186-9/fulltext

04/24/2026

Watch highlights from Day 2 of

04/23/2026

Clinical endocrinology is evolving. Your learning should too. AACE Self-Assessment Program (ASAP) is being reimagined, not only as a board review tool, but as a next-generation learning portfolio designed for lifelong clinical excellence. ASAP Microlearning Volume 1 is complimentary for Engaged AACE Community members. Join now to receive discounts on all of our educational opportunities.

AACE Self-Assessment Program (ASAP) Microlearning Volume 1 is designed for practicing clinical endocrinologists. This case-based microlearning course delivers high-yield clinical insights across the full spectrum of endocrine care. The program features six focused modules, each built around real-wor...

04/23/2026

Now available! AACE Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update

This updated algorithm provides evidence-based visual guidance in graphic algorithms and a summary of evidence and considerations to assist health care professionals with the diagnosis and management of adults with prediabetes and type 2 diabetes in shared decision-making to improve care.

04/23/2026

AACE launched the Diabetes Center of Excellence (CoE) designation — an international recognition program for non-US based healthcare organizations demonstrating leadership, measurable outcomes, and excellence in diabetes care.

Cohort 2027 preapplications are now open to international (non-U.S.) institutions.

Deadline: July 30, 2026.

A new designation recognizing international institutions that demonstrate leadership, measurable outcomes, and excellence in diabetes care

04/23/2026

Catch up on highlights from Day 1 of

04/22/2026

Understanding which patients are susceptible to adverse effects of sustained hypophosphatemia in the setting of intravenous iron will aid in preventing skeletal complications of osteomalacia and fractures. Read more: https://www.endocrinologydiabetes.org/article/S3050-9157(25)00157-2/fulltext

04/22/2026

Our Health Care Advocacy Webinar Series is now available as a free, 4-part on-demand program designed for endocrinologists and health care professionals.

Strengthen your voice in health care advocacy with expert-led insights on driving impact at the institutional, state, and national levels. This series explores emerging issues, including AI, team-based care, and telemedicine, and features live Q&A discussions with AACE experts.

Learn more: https://pro.aace.com/advocacy/aace-healthcare-advocacy-webinar-series.

Register for our free AACE Health Care Advocacy Webinar Series—designed for endocrinologists and health care professionals—focused on strengthening your voice in health care advocacy.

04/21/2026

This study reports real-world experience with an innovative approach to reduce DKA risk in this population: the combination of once-daily subcutaneous basal insulin and hybrid closed-loop insulin pump therapy. Read more:

We assessed the impact of adding subcutaneous basal insulin to hybrid closed-loop insulin pump therapy on diabetic ketoacidosis (DKA) rates and glycemic outcomes in adults with type 1 diabetes (T1D) and recurrent DKA.

04/20/2026

A survey of AACE members in the United States showed that levothyroxine is the preferred agent prescribed for hypothyroidism, as with similar studies conducted by the Treatment of Hypothyroidism in Europe by Specialists collaborative. Read more: https://www.endocrinologydiabetes.org/article/S3050-9157(25)00151-1/fulltext

04/17/2026

These findings highlight the potential role of approved pharmacologic therapies for obesity, particularly liraglutide and naltrexone/bupropion, as treatment options for individuals with both obesity and binge eating, underscoring the need for standardized outcomes and further trials to guide clinical practice. Read more: https://www.endocrinepractice.org/article/S1530-891X(25)01266-2/fulltext